The listed hours run from 9:00 am to 6:00 pm. Attendance costs $799.
The International Conference on Genetics, Genomics & Precision Medicine is scheduled for September 27-29, 2027, in Barcelona. Attendees are expected from academia and clinical research. Biotechnology representatives are also expected, alongside people from the healthcare industry.
Its stated theme is “Shaping the Future of Healthcare Through Genomic Innovation and Precision Medicine Excellence.” The program is set to include keynote lectures and plenary sessions. Technical presentations will sit alongside panel discussions. Workshops and poster sessions are also planned.
From genomic methods to tailored care
The scientific program lists genetic disorders and genomic sequencing. It also names molecular diagnostics. Bioinformatics and pharmacogenomics appear on the agenda. Gene therapy has a place, as do AI applications in precision medicine. These subjects span research methods and ways to use genetic information in treatment decisions.
The National Institutes of Health’s All of Us Research Program offers a large-scale example of the data infrastructure behind precision medicine. Information from more than 747,000 participants combines genomic data with electronic health records. Researchers can access it through the All of Us program.
Gene therapy can deliver genetic material with viral vectors. Another approach edits DNA with technologies such as CRISPR. These treatments aim to address or compensate for the underlying cause of disease. Development also brings manufacturing challenges. Costs and long-term monitoring matter too.
An American Society of Health-System Pharmacists review reported that the FDA had approved 38 cell and gene therapy products by the end of 2025. Orphan-drug status applied to 86.8% of those products. An accelerated regulatory pathway applied to 92.1%. A single pivotal study supported approval for 73.7%, according to the ASHP review.
Work elsewhere in the field includes Penn Medicine's Smilow Center, backed by a $25 million gift. The center is intended to speed research on gene editing and targeted therapies for heart disease. Regulatory efforts are changing too: FDA’s Expedited IND Pilot Program for cell and gene therapies launched on September 15, 2026.
The pilot provides for earlier discussions with sponsors and qualified research institutions as they prepare first-in-human study applications. Applications are due by October 30, 2026. The FDA expects to select eight to ten sponsor-institution pairs by December 18, 2026, under the program described by Inside Precision Medicine.
